[Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection?].
作者信息
Nagahara Akihito, Sato Nobuhiro
机构信息
Department of Gastroenterology, Juntendo University School of Medicine.
出版信息
Nihon Rinsho. 2005 Nov;63 Suppl 11:421-5.
PMID:16363572
Abstract
摘要
相似文献
1
[Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection?].
Nihon Rinsho. 2005 Nov;63 Suppl 11:421-5.
2
[Eradication therapy for clarithromycin-resistant and metronidazole-resistant Helicobacter pylori infection].
Nihon Rinsho. 2002 Feb;60 Suppl 2:460-4.
3
[Helicobacter pylori eradication therapy for children].
Nihon Rinsho. 2005 Nov;63 Suppl 11:470-3.
4
Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance.
Am J Gastroenterol. 1998 Jan;93(1):2-3. doi: 10.1111/j.1572-0241.1998.002_c.x.
5
[Triple therapy for eradication of Helicobacter pylori in Japan].
Nihon Rinsho. 2005 Nov;63 Suppl 11:409-13.
6
[Triple therapy with faropenem, proton pump inhibitor (PPI), and amoxicillin for clarithromycin-resistant H. pylori eradication].
Nihon Rinsho. 2002 Feb;60 Suppl 2:452-4.
7
[Eradication of Helicobacter pylori in patients with end-stage renal disease undergoing dialysis treatment].
Nihon Rinsho. 2005 Nov;63 Suppl 11:486-8.
8
[PPI plus bismuth-based quintuple therapy].
Nihon Rinsho. 2005 Nov;63 Suppl 11:452-8.
9
[Guidelines in the management of H. pylori infection in Japan].
Nihon Rinsho. 2005 Nov;63 Suppl 11:12-6.
10
[Ecabet sodium (ECA) + PPI + AMPC therapy for clarithromycin-resistant Helicobacter pylori infections].
Nihon Rinsho. 2002 Feb;60 Suppl 2:455-9.
Zotero 插件